Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FSPG PET Imaging in Ovarian Carcinoma
NCT02872519Phase 1Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jun 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of Florilglutamic acid F-18 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Standard Uptake Value at 2 years and Number of lesions detected at 2 years. Planned start Jun 2018; status: withdrawn.
02
Drugs
Florilglutamic acid F-18
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02872519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872519.